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Abstract: Acute otitis media and otitis media with effusion are common childhood disorders, 
a source of significant morbidity, and a leading cause of antibiotic prescription in primary health 
care. Although effective treatments are available, some shortcomings remain, and thus better 
treatments would be welcome. Recent discoveries within the field of otitis media research relat-
ing to its etiology and pathogenesis have led to further investigation aimed at developing novel 
treatments. This article provides a review of the latest evidence relating to the understanding of 
acute otitis media and otitis media with effusion, current treatment strategies, their limitations, 
new areas of research, and novel strategies for treatment.
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Introduction
Otitis media (OM) is a group of complex infective and inflammatory conditions affect-
ing the middle ear, with a variety of subtypes differing in presentation, associated 
complications, and treatment. OM is a leading cause of health care visits worldwide, 
and its complications are important causes of preventable hearing loss, particularly in 
the developing world.1 This article provides an update on recent scientific achievements 
within the field of OM research and clinical management.
OM is pathology of the middle ear and middle ear mucosa, behind the ear drum 
(tympanic membrane). The middle ear is a cavity containing the ear ossicles (malleus, 
incus, and stapes), with the eustachian tube placed anteriorly (leading to the nasophar-
ynx), the mastoid air cells posteriorly, tympanic membrane laterally, and the inner ear 
medially. Other important nearby structures are the brain and meninges superiorly and 
the sigmoid sinus posteriorly, and any infection of the middle ear can spread to sur-
rounding structures with serious results. The middle ear is lined by modified respiratory 
epithelium, including ciliated cells and goblet cells; the epithelium produces mucins 
that are normally transported down the eustachian tube.
Different types of OM present in different ways.2 Acute OM (AOM) usually affects 
children aged under 2 years, and presents with acute onset symptoms and signs of 
otalgia and fever, in a child that is systemically unwell. It is acute inflammation, and 
may be caused by bacteria or viruses. A particular subtype of AOM is acute suppura-
tive OM, which is characterized by the presence of pus in the middle ear. If the ear 
drum perforates (this occurs in approximately 5%, although higher rates have been 
reported)3–5 then ear discharge will be present also; the perforation usually heals 
spontaneously.3 AOM is one of the commonest childhood infectious diseases; in the 
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majority of cases the disease is self-limiting,6 but it has high 
morbidity, although mortality rates are generally low.7,8
A relatively common complication of AOM is acute 
mastoiditis, defined as acute inflammation of the mastoid 
periosteum and air cells; this occurs when AOM infection 
spreads from the middle ear itself into the mastoid air cells 
and their covering periosteum. The incidence is 1.2–6.0 in 
100,000 and usually occurs in children under 2 years of 
age.9 Patients usually present with the symptoms of AOM 
plus post-auricular swelling and mastoid tenderness. The 
condition is more serious than uncomplicated AOM, typi-
cally requiring hospital admission, intravenous antibiotics, 
and surgery if abscess has formed or mastoiditis has not 
responded to antibiotics.
In contrast to AOM and acute mastoiditis, OM with effu-
sion (OME) is a chronic inflammatory condition. It typically 
affects children between 3 and 7 years old. It is character-
ized by the presence of an effusion, glue-like fluid behind 
an intact tympanic membrane in the absence of signs and 
symptoms of acute inflammation;10 for this reason the com-
monest reported symptom is hearing loss, which may lead 
to speech delay or educational problems. Histologically it is 
a chronic inflammatory condition, characterized by inflam-
mation in the middle ear mucosa, overproduction of mucin 
and production of altered, more viscous mucin.11 Mucin 
is the predominant component of the middle ear effusion 
responsible for the thick viscous properties of the “glue;” 
numerous other components including bacteria have been 
identified in the middle ear effusion also.11
The hearing loss in OME is often transient as the middle 
ear effusion frequently resolves spontaneously,10 espe-
cially if OME follows an episode of AOM;6 when OME is 
 discovered on screening of asymptomatic children, it resolves 
in 63% by 3 months and in 88% by 1 year.6 For this reason 
a “watch and wait” period should be adopted and treatment 
only offered to those in whom an effusion is persistent. 
When OME is persistent, particularly if bilateral and early 
in life, it may impact negatively on speech development, 
education, and behavior, although the extent to which OME 
affects these factors and quality of life can be variable and 
is controversial.10
OME has a lower prevalence in adults and is then 
frequently associated with other underlying diagnoses. 
Finkelstein et al12 described paranasal sinus disease as the 
dominant factor in 66% of adults with OME, with other 
causes including smoking-induced nasopharyngeal lymphoid 
hyperplasia and adult onset adenoidal hypertrophy in 19% 
of cases, and head and neck tumors (mainly nasopharyngeal 
carcinomas) in 4.8%; in only 1.8% of patients was no 
cause identified. For these reasons OME in adults is treated 
with a greater degree of suspicion, particularly when 
unilateral. Adults diagnosed with OME should be evalu-
ated for  additional underlying conditions and then treated 
accordingly.
Two additional inflammatory conditions of the middle 
ear are chronic suppurative OM (CSOM), characterized 
by the presence of long-standing suppurative middle ear 
inflammation, usually with a persistently perforated tympanic 
membrane, and cholesteatoma, which occurs when kerati-
nizing squamous epithelium (skin) is present in the middle 
ear (normal middle ear is lined by modified respiratory epi-
thelium). Patients with CSOM often experience persistent 
otorrhea, but this symptom is not obligatory; they can also 
experience hearing loss, tinnitus, otalgia, and pressure sensa-
tion.13 The chronic nature of the disease and permanent perfo-
ration mean that treatment is usually multifaceted, requiring 
antimicrobial agents and surgery. Cholesteatoma typically 
presents with chronic smelly ear discharge, and can be diag-
nosed when squamous epithelium and keratin are seen in the 
middle ear; the only curative treatment is surgical.
Although the different types of OM have been described 
here as discrete diseases with a discrete cluster of clinical 
symptoms, signs, sequelae, and treatments, in reality there is 
a great degree of overlap between the different types, so that 
OM can be seen as a continuum/spectrum of diseases. AOM, 
CSOM, and cholesteatoma are also associated with a num-
ber of important intracranial and extracranial complications 
including mastoiditis, meningitis, brain abscess formation, 
and sigmoid sinus thrombosis; the early detection of these is 
especially important to limit morbidity and mortality.
Epidemiology
It is thought that between 50% and 85% of children experi-
ence at least one episode of AOM by 3 years of age with the 
peak incidence being between 6 and 15 months.14 OME is 
the commonest cause of hearing impairment in children in the 
developed world, and can affect as many as 80% of children 
at some stage,10,11 with approximately 2.2 million new cases 
of OME annually in the United States of America.15
Young children are more prone to AOM and OME due to 
an anatomical predisposition; the eustachian tube is shorter, 
more flexible, and horizontal which allows nasopharyngeal 
pathogens to enter the middle ear with relative ease. In fact 
nasopharyngeal dimensions have been shown to be smaller 
in children suffering from repeated attacks of AOM.16 The 
eustachian tube matures by 7 years old; this may explain 
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the relative decline in the incidence of OM after this age. 
Immaturity of the immune system may also be a contribut-
ing factor to AOM.
Certain populations are known to have a higher incidence 
of OM; eg, Australian Aboriginal children17 and children 
from Greenland.18 Other studies have identified numerous 
potential lifestyle and sociodemographic contributing fac-
tors, although a degree of controversy exists regarding 
the relative importance of the risk factors, as well as their 
interdependence. These include host risk factors including 
age (,5 years old), male sex, ethnicity (white), low birth 
weight (,2.5 kg), premature birth (,37 weeks gestation), 
and pacifier use, as well as environmental factors including 
season of birth (spring/summer), lack of breastfeeding, day 
care attendance, number of siblings, parental education/
employment (lower socioeconomic groups), household 
income (below poverty level), personal and family history 
of ear infections, and prenatal/postnatal exposure to cigarette 
smoke.19 More recently, atopy20 and specific gene abnormali-
ties (TLR421 and FBX01122) have also been implicated as host 
risk factors for OM.
A recent worldwide systematic review estimated that there 
are 709 million new cases of AOM annually, with greater than 
half in children under 5 years of age, and found 31 million 
new cases of CSOM, with 22.6% in children under 5 years.1 
The review also estimated that OM-related hearing impair-
ment was present in 30.82 per 10,000 population, and 21,000 
deaths were attributable to OM-related complications. Other 
worldwide studies have estimated mortality figures as high as 
28,000 a year as a result of OM-related complications, mainly 
due to brain abscesses and meningitis.23 Mortality is typically 
associated with CSOM rather than other types of OM. Thus, 
it is clear that OM is not just something that affects quality 
of life, but has a very real mortality attached to it.
The annual prevalence of OM diagnoses in the United 
States of America fell by 28% between 1997 and 2007 from 
345 to 247 per 1,000 children,19 with the decline attributed 
to the introduction of the pneumococcal conjugate vaccine, 
which appears to have decreased the number of individuals 
suffering from OM in numerous studies.19,24
Etiology
The etiology of OM is multifactorial and relates to ana-
tomical variations, pathophysiology including the interaction 
between microbial agents and host immune response, and 
cell biology of the middle ear cleft (mastoid, middle ear 
cavity, eustachian tube) and nasopharynx.25,26 Viral upper 
respiratory tract infections often precede or coincide with 
episodes of AOM; examples include respiratory syncytial 
virus, adenovirus, and cytomegalovirus.27 Viral infections 
are now thought to have a pivotal role in AOM progression, 
and recent randomized controlled trials have demonstrated 
the role of antiviral treatment for AOM.28 It is thought that 
viral infection of the nasopharynx creates an environment 
that promotes bacterial colonization, adhesion to cells, and 
invasion of the middle ear.27
The bacteria commonly implicated in upper respi-
ratory tract infections are also those most frequently 
isolated from middle ear effusions in AOM. These are 
Streptococcus pneumoniae, Haemophilus influenzae, 
Moraxella catarrhalis, and to a lesser extent Staphylococcus 
aureus, and Streptococcus pyogenes; they are believed to 
enter the middle ear cleft via the eustachian tube. There is 
a variable incidence in the detection of these bacteria from 
effusions in AOM, but S. pneumoniae and H. influenzae 
have been detected most frequently in recent studies.29,30 
Similar bacteria have also been cultured from fluid in OME, 
although different studies in different circumstances in dif-
ferent countries may produce different findings. In general, 
the bacteria in OME are similar to those seen in recurrent 
AOM (RAOM).31
Upper respiratory tract infections can lead to mucosal 
congestion in the eustachian tube and nasopharynx. The 
resultant congestion prevents normal eustachian tube function 
and pressure regulation is altered within the middle ear. If 
sustained, aspiration of nasopharyngeal pathogens can occur 
into the middle ear. The presence of these pathogens then 
stimulates inflammation and pus collection within the middle 
ear, resulting in clinical symptoms of AOM. During this 
inflammatory period, the middle ear ossicles are less mobile 
and may be subject to resorption,32 which could even lead to 
permanent conductive hearing loss. Studies have described 
patients with smaller mastoid cavities as having greater risk 
of developing chronic middle ear disease;27 however, whether 
this effect is causative is controversial. Patients with chronic 
infection may also develop sensorineural hearing loss sec-
ondary to ototoxicity.
Pathogenesis of AOM is complex and multifactorial. 
Figure 1 illustrates some of the complex interactions that 
may lead to AOM development.
OME is histologically a chronic inflammatory condition. 
An underlying stimulus leads to an inflammatory reaction33 
with production of more mucin and altered, more viscous 
mucin types,11 which then overwhelms normal mucociliary 
clearance of the middle ear with functional blockage of the 
eustachian tube, resulting in the accumulation of a thick, 
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mucin-rich middle ear effusion.26 Over the last few years it 
has become recognized that bacterial biofilms are important 
in the etiology of OME.34,35 These three-dimensional com-
munities of bacteria, attached to a surface, encased in self-
produced extracellular matrix, and with altered phenotype, 
are thought to exert a chronic inflammatory stimulus leading 
to OME. Chronic biofilm colonization of the adenoids may 
act as a reservoir for bacteria entering the middle ear cleft in 
OM.36 The overexpression of mucin genes is also exacerbated 
by cigarette smoke.37 OME may occur as a consequence of 
AOM taking an extended period of time to resolve; eg, weeks 
or months.
Other theories for the development of OME have been 
postulated. Eustachian tube dysfunction was often thought 
to cause middle ear effusion through negative pressure in 
the middle ear cleft; recently, however, a more complex role 
for the eustachian tube has been described. It is thought 
to have a role in pressure regulation, secretion clearance, 
and protection from nasopharyngeal pathogens.26 Reflux of 
gastroesophageal acid can also contribute to eustachian tube 
dysfunction and subsequent OM.38 Genetic factors, including 
those influencing host immune response also play a role.39 
The complex interplay of various factors leading to OME is 
shown in Figure 2.
CSOM typically occurs when chronic middle ear 
infection prevents the healing of an acute perforation. 
 Cholesteatoma can also result in chronic middle ear infec-
tion and inflammation, but the etiology is complex. CSOM 
is frequently seen in children; in developed countries it is 
often a result of ventilation tube insertion (ventilation tubes 
extrude and leave the tympanic membrane perforated), whilst 
in developing countries CSOM is often a complication of 
AOM with  perforation.40 Chronic or inadequately treated 
middle ear infection in the presence of a perforation may 
allow squamous epithelial migration over the free edges 
of a perforation, making it permanent. Immunological and 
genetic factors, in addition to eustachian tube characteristics, 
play a role in the etiology of CSOM; however, many aspects 
require further investigation.13 Although bacterial cultures 
are useful in treating drug-resistant organisms, exhaustive 
studies have established that 90%–100% of chronically 
discharging ears yield two or greater isolates of aerobic and 
anaerobic bacteria.23
Diagnosis
Various guidelines exist to aid clinicians in diagnosing 
OM and its subtypes. AOM is differentiated from OME 
and CSOM based on the history and examination findings. 
 Myringotomy (surgical incision of the ear drum) is 
 considered the gold standard for the diagnosis of middle ear 
fluid;26  however, it is not practical to subject every child to 
this surgical procedure when the diagnosis can be made on 
the basis of assessment in the clinic.
AOM is a purulent middle ear process, therefore the 
signs and symptoms consistent with acute inflammation are 
 present. AOM typically has a short history, and is commonly 
associated with fever, otalgia, irritability, otorrhea, lethargy, 
anorexia, and vomiting; the symptoms alone lack sensitivity 
and specificity for diagnosis.41 The American Academy of 
Pediatrics guidelines42 state that AOM should be diagnosed 
in children with moderate to severe bulging of the tympanic 
membrane or new onset otorrhea not secondary to otitis 
externa. The diagnosis may also be made with mild bulging 
of the  tympanic membrane with otalgia or intense tympanic 
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membrane erythema; in the absence of a middle ear effusion 
(assessed with pneumatic otoscopy or tympanometry) the 
diagnosis is unlikely. Pneumatic otoscopy and tympanometry 
assess mobility of the ear drum, and if a non-perforated ear 
drum is immobile this indicates the presence of a middle 
ear  effusion; both techniques rely on varying the ear canal 
pressure, with pneumatic otoscopy visualizing the ear drum 
directly and tympanometry assessing mobility by means of 
sound reflection. If a child has three episodes of AOM within 
a 6-month period, or four in 1 year, the condition is referred 
to as RAOM.43
OME may occur as a residual effect of AOM, or there 
may be no preceding history. Clinical features include a 
history of hearing difficulties, poor attention, behavioral 
problems, delayed speech and language development, 
clumsiness, and poor balance.41 Otoscopy is vital in mak-
ing the diagnosis, with sensitivity and specificity quoted 
at 90% and 80%, respectively;44 this may be increased by 
using pneumatic otoscopy. The clinical findings are vari-
able, and include abnormal color (eg, yellow/amber/blue), 
retracted/concave tympanic membrane, and air–fluid levels. 
Further evidence is obtained with an audiogram (hearing 
testing typically showing mild conductive hearing loss) and 
tympanogram (showing an immobile ear drum or negative 
middle ear  pressure). Parental concerns about hearing loss 
may be unreliable and should not be a substitute for formal 
audiological investigation.26
CSOM is diagnosed when a permanent tympanic 
 perforation is detected alongside middle ear mucositis with 
or without persistent otorrhea; the discharge should be 
 present for a minimum of 2–6 weeks.40 The history is crucial 
in distinguishing between CSOM, otitis externa, and AOM; 
in CSOM pain is not usually a predominate feature and ear 
discharge is likely to be of a longer duration. The diagno-
sis is confirmed with otoscopy which will usually detect a 
tympanic membrane perforation and associated middle ear 
discharge.
Current treatment
There are well established recommendations for the medical 
and surgical management of different types of OM.45
In general, AOM follows a favorable course without 
antibiotic treatment, with analgesia and antipyretics being 
important. Meta-analyses have demonstrated that approxi-
mately 80% of children have spontaneous relief of AOM 
within 2–14 days.46–48 In children aged ,2 years the results 
are less clear and resolution may be as low as 30% in a 
few days.49 The overall high rates of resolution mean that 
it may be appropriate to simply observe children diagnosed 
with AOM in the absence of suspected complications.
Current USA guidelines for the treatment of AOM 
recommend that antibiotics should be used in children 
aged over 6 months when unilateral or bilateral AOM is 
severe (moderate to severe otalgia, otalgia lasting at least 
48 hours, temperature 39°C).42,50 Antibiotics should also be 
prescribed if AOM is not severe but is bilateral in a child 
aged 6–23 months. In the case of non-severe unilateral AOM 
in a child aged 6–23 months, or non-severe unilateral/bilat-
eral AOM in a child aged 24 months or older, antibiotics 
may be prescribed or observation offered; if observation is 
chosen, a mechanism should be in place to give antibiotics 
if symptoms do not improve in 48–72 hours. In addition to 
assessment of the child’s condition, the thoughts of caregivers 
or parents must be considered and decisions made jointly. 
Pain assessment and management is an essential aspect of 
treating AOM. Importantly, an initial period of observation 
is not associated with a greater risk of complications when 
compared to those receiving immediate treatment.46
The routine prescription of antibiotics for AOM ranges 
from 31% in the Netherlands to 98% in the USA and 
 Australia.41 The antibiotic of choice is amoxicillin unless 
the child has taken this in the past 30 days or is suffering 
from concurrent purulent conjunctivitis. Antibiotics with 
additional beta-lactamase cover should be used in these cases 
or when there is RAOM or a history of AOM unresponsive 
to amoxicillin. Patient allergies should also be considered 
and alternative agents used in situations where penicillin 
allergy exists.
For RAOM, surgically inserted ventilation tubes should 
be considered if RAOM is associated with a persistent middle 
ear effusion between AOM attacks.51 Prophylactic antibiot-
ics are generally not recommended for RAOM, although a 
systematic review has noted that they are effective;52 due 
to concerns about long duration of antibiotic exposure and 
potential side effects,42 ventilation tubes generally end up 
being the preferred option. Both ventilation tubes and pro-
phylactic antibiotics are only effective for the duration of 
ventilation tube stay time (most ventilation tubes extrude 
6–9 months after placement) or for as long as antibiotics are 
taken, respectively.
As with AOM, many children with OME do not require 
treatment due to high rates of spontaneous resolution. 
 However, when OME is bilateral and persistent for more 
than 3 months, the chances of natural resolution are much 
lower and treatment may be beneficial. Current UK and USA 
guidelines50,53 recommend a 3-month period of observation 
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with serial audiometry and assessment of the degree of 
hearing loss and the impact on a child’s development before 
determining the need for treatment, although guidelines are 
not always followed.54 Guidelines recommend either surgery 
in the form of ventilation tubes or hearing aids. Ventilation 
tube insertion is associated with a number of risks, which 
include purulent otorrhea (10%–26%), myringosclerosis 
(39%–65%), retraction pockets (21%), and persistent tym-
panic membrane perforations (3%, although with longer-stay 
T-tubes, up to 24%).55 In addition, once tubes extrude OME 
may return, with one trial of short-term tubes noting that 
20%–25% of children required a second set of ventilation 
tubes within 2 years.56 Adenoidectomy is also thought to have 
a role in preventing recurrent OME,57 but due to associated 
risks it is typically not recommended as a primary treatment 
of OME, unless there are frequent or persistent upper respira-
tory tract infections.53 Numerous other treatments for OME 
have been trialled, including antibiotics, antihistamines, and 
steroids, but are not currently recommended.53
Unlike AOM and OME, the definitive management for 
CSOM is usually surgical,13 with a variety of techniques 
described to repair the ear drum and remove infection. Con-
servative management is appropriate in select patient groups, 
with the aim of reducing bouts of recurrent discharge and infec-
tion and therefore associated hearing loss.58 The commonest 
conservative treatment is regular aural toilet followed by the 
use of antibiotics, antiseptics, and topical steroids.40 Topical 
quinolones (eg, ciprofloxacin) have been found to be the most 
effective treatment in a recent Cochrane review,59 but although 
these are licensed in the USA, they are currently not licensed 
as ear drops in the UK. Many of the frequently used ear drops 
are based on aminoglycosides, and although concerns exist 
about their potential ototoxicity when used in the presence of 
tympanic membrane perforation, the current consensus is that 
their use is safe in short, supervised courses, and less ototoxic 
than the infection itself.60 Conservative management alone is 
typically chosen based on patient choice, the absence of surgi-
cal options, when the effected side is the only hearing ear, or 
when the risks of surgery outweigh its benefit.
Emerging strategies  
in prevention and treatment
Currently, AOM is a common reason for antibiotic use, and 
the treatment of OME and AOM with ventilation tube inser-
tion is the commonest cause for surgery in children in the 
developed world. Yet antibiotic use may lead to emergence 
of resistance and side effects, whilst ventilation tubes usually 
require a general anesthetic, extrude after a period of time, 
and many children need repeat surgery. Better treatment 
of AOM and OME would therefore be welcome. The ideal 
treatment would be preventative, effective, immediate, with 
sustained activity, and nontoxic; current research is focusing 
on achieving these targets.
Genetics
The genetic factors resulting in predisposition to OM are 
not well understood, although a few genetic targets have 
been identified. AOM and CSOM heritability estimates of 
40%–70% have been reported; however, the majority of genes 
underlying this susceptibility are yet to be identified.61 It is 
likely that there are mixtures of innate defense molecules 
which may or may not become defective, leading to OM 
susceptibility. Potential therapeutic targets are the genes 
regulating mucin expression, mucus production, and host 
response to bacteria in the middle ear.39 Better understand-
ing of the genetics of OM could also lead to development 
of preventative measures, or minimization of risk factors in 
susceptible individuals.
Genetics research has also identified the important 
role for hypoxia in OME, and this may (partly) explain the 
effectiveness of ventilation tubes, which would relieve any 
hypoxia in the middle ear. Mouse models have been used to 
demonstrate a role for hypoxia inducible factor and vascular 
endothelial growth factor (HIF-VEGF) signaling pathways 
in the pathogenesis of OME, and these may be potential 
future therapeutic targets for the treatment of OME.62 Animal 
 models of AOM and OME allow the whole disease process 
to be analyzed and are subject to experimental manipula-
tion; for these reasons significant efforts have been made to 
improve the models used to assess this condition; the most 
recent advances in this field include knock-out mice with 
spontaneous OM (using MyD88 and TLR2) and induced 
OM (using TLR2, 4, 9, Trig, dynactin subunit 4) and animal 
models of bacterial and viral infection.39
Pneumococcal vaccine
Preventative measures for the development of OM are 
important in limiting the impact of this disease, associated 
antibiotic prescription, and emerging bacterial resistance. 
Promising candidate antigens for vaccination have been 
identified in S. pneumoniae (the commonest cause of 
AOM), nontypeable H. influenza, and M catarrhalis. The 
pneumococcal conjugate vaccine was primarily developed 
to address invasive pneumococcal disease (ie, pneumonia), 
but has proven useful in targeting the commonest cause of 
AOM.63 It has therefore attracted a lot of recent attention.
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Numerous systematic reviews have confirmed the efficacy 
of pneumococcal vaccine in preventing pneumococcal 
AOM.63,64 Following introduction of the 7-valent pneumococ-
cal conjugate vaccine (PCV7), childhood incidence of AOM 
declined in the USA and Canada. In children aged under 
2 years, a 43% reduction in AOM, 42% reduction in antibiotic 
prescription, and 32% reduction in AOM-related costs has been 
observed.65 Canadian studies have shown an overall decline 
of 25.2% in AOM from 2000 to 2007, with 13.2% attributed 
to the vaccine, and with the largest impact in children under 
2 years old.64 Significant reductions in nasopharyngeal vaccine 
serotypes have also been noted after PCV7 introduction.66 
Whilst PCV7 resulted in the decrease of serotypes covered by 
the vaccine, pneumococcal serotype 19A increased in carriage 
and prevalence as an otopathogen;67 furthermore, isolates of 
S. pneumoniae serotype 19A resistant to all US Food and Drug 
Administration (FDA)-approved drugs for use in children to 
treat AOM have been characterized.68
Despite promising results, concerns exist over the long-term 
benefit from vaccination. A recent study has highlighted con-
cerns regarding increasing incidence of AOM-related complica-
tions.69 Following the introduction of vaccination, AOM-related 
complications including mastoiditis and other intracranial 
complications fell; however, they returned to pre-vaccination 
levels after a few years.69 This fall and rise has also been noted 
in pneumococcal infections from other sites, although in general 
these infections appear to be less common than they were before 
vaccination was introduced.70 Serotype replacement remains a 
concern, as does a rise in non-pneumococcal pathogens.69
One potential method to overcome vaccine resistance 
would be to formulate a vaccine from broadly conserved 
protein antigens; this would be serotype-independent and 
theoretically not associated with serotype replacement.63 This 
form of vaccine could be more affordable and particularly 
useful in developing countries, where the need is greatest.71 
Newer pneumococcal vaccines with protection against addi-
tional serotypes have been developed, including the 13-valent 
pneumococcal vaccine and the 11-valent pneumococcal 
polysaccharide conjugate vaccine with protein D as a carrier, 
which may also have additional benefit against nontypeable 
H. influenzae OM. The role of maternal immunization strate-
gies may also be interesting in evaluating benefit to infants.
Developments in microbiology  
and bacterial resistance
Widespread use of antibiotics is commonly known to lead 
to resistance. Antibiotic-induced stress can increase the rate 
of genetic transformation of S. pneumoniae in an effort to 
generate a resistant phenotype. Furthermore, exposure to 
sub-minimum-inhibitory-concentration levels of antibiotics 
increases the pneumococcal mutation rate, which may lead 
to antibiotic resistance.72 Penicillin has traditionally been the 
antibiotic of choice for S. pneumoniae, likewise macrolides 
and fluoroquinolones are also effective.73 The European 
Centre for Disease Control and Prevention provides antimi-
crobial resistance surveillance of 27 European countries and 
shows an overall slight increase in the susceptibility rates of 
S. pneumoniae to penicillin and macrolides between 2009 and 
2011.74,75 The data from 2011 show 8.8% of S. pneumoniae 
isolates were non-susceptible to penicillin and 0.02% were 
resistant; additionally, 14.6% and 14.1% of pneumococcal 
isolates were non-susceptible and resistant to macrolides, 
respectively, and 5.8% of all isolates were non-susceptible 
to both.75 Resistance to fluoroquinolones has also been dem-
onstrated.72,75 Similarly, nontypeable H. influenzae, the main 
serotype responsible for OM, frequently produces beta-lac-
tamase, and is thus resistant to ampicillin;29,76,77 amoxicillin/
clavulanate may be preferred,77 but a study in Spain found 
that 13% of the nontypeable H. influenzae isolates were even 
amoxicillin/clavulanate resistant.29
An additional therapeutic problem is the involvement of 
biofilms in OME. The biofilm mode of growth contributes 
to persistence through a variety of mechanisms, including 
phenotypically altered “persister cells” that can repopulate 
biofilm bacteria;78,79 defense by the exopolysaccharide matrix, 
which physically blocks host defense mechanisms, leading 
to an ineffective inflammatory response; and horizontal gene 
transfer which can increase virulence.79 The high rate of OME 
reoccurrence, 20%–25% after ventilation tube removal,80 
could also be explained by biofilm persistence because venti-
lation tubes remove the effusion but may not necessarily treat 
the underlying biofilm.56  Furthermore, biofilms can develop 
recalcitrance and resistance to antibiotics.81 Biofilm bacteria 
have a decreased growth rate as compared to the planktonic 
form, and many antibiotics’ target sites are downregulated 
in this state. The matrix and aggregation of bacteria can 
physically block antibiotics from reaching some popula-
tions in the biofilm at levels above the minimum inhibitory 
concentration.81 Resistance, which differs from recalcitrance 
in that it results from genetic mutations, can arise due to an 
increased state of  hypermutability.82  Clinically, this means 
that biofilm eradication typically requires antibiotic levels 
that are 10–1,000 times higher than the levels needed to 
inhibit the planktonic form.83 Levels of antibiotics that high 
would be difficult to safely achieve systemically, but they 
could be achieved with local drug administration.57
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The understanding that biofilms are important in the 
pathogenesis of OME opens up the potential for new 
treatment strategies based on biofilm eradication, includ-
ing novel methods of delivering antibiotics to the site of 
infection.
Drug delivery to the middle ear
Local delivery of antibiotics directly to the ear as a treat-
ment for OM, as opposed to systemic administration, 
could be an efficient strategy and a safer one in view of 
the risk of systemic toxicity, especially if a high dose is 
required.84 Broadly speaking, there are two strategies, 
transtympanic and intratympanic delivery. Transtympanic 
delivery relies on the possibility of therapeutic molecules 
diffusing through the ear drum, from the ear canal into the 
middle ear; this can be facilitated by the use of chemical 
permeation enhancers. In vivo experiments have shown 
this to be a promising future strategy,85 although it is not 
currently in clinical use. Therapeutic agents can also be 
delivered transtympanically as magnetic particles,86 but 
again this is not currently in clinical use as a treatment for 
OM. A possible major limitation of transtympanic delivery 
relates to the limited amount of drug that actually can travel 
across the ear drum.
An alternative is delivery of drugs directly to the middle 
ear, which would allow a much greater amount of drug to 
reach the intended site of action. However, the downside 
is the need to incise or puncture the ear drum in order to 
achieve drug delivery. A variety of different methods have 
been proposed, including drug delivery gels87 and antibiotic 
pellets,56 with the latter strategy shown to eradicate S. aureus 
biofilms in vitro.
The safety of these administration methods should 
be assessed prior to widespread clinical use. Any drug, 
as well as delivery carrier, has the potential to be toxic 
when delivered directly to the ear in large quantities. 
Potentially, the middle ear or the inner ear may be affected 
by toxicity, with effects on hearing and/or balance. Thus, 
comprehensive toxicity testing is warranted before clini-
cal application.
Conclusion
OME and AOM are a significant cause of patient morbidity 
and cost to the health service. Current guidelines dictate 
their treatment, but significant shortcomings remain. Recent 
advances in the fields of microbiology, biofilm study, vaccine 
developments, genetics, and drug delivery offer the potential 
for better treatments in the future.
Acknowledgment
All authors have participated sufficiently to take public 
responsibility for the content of this article and qualify for 
authorship in accordance with the journal’s guidance.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Monasta L, Ronfani L, Marchetti F, et al. Burden of disease caused 
by otitis media: systematic review and global estimates. PLoS One. 
2012;7(4):e36226.
 2. Senturia BH, Bluestone CD, Klein JO, et al. Report of the ad hoc 
committee on definition and classification of OM and OME. Ann Otol 
Rhinol Laryngol. 1980;89:3–4.
 3. Berger G. Nature of spontaneous tympanic membrane perforation in acute 
otitis media in children. J Laryngol Otol. 1989;103(12):1150–1153.
 4. Pukander J. Clinical features of acute otitis media among children. Acta 
Otolaryngol. 1983;95(1–2):117–122.
 5. Kalu SU, Ataya RS, McCormick DP, Patel JA, Revai K, Chonmaitree T. 
Clinical spectrum of acute otitis media complicating upper respiratory 
tract viral infection. Pediatr Infect Dis J. 2011;30(2):95–99.
 6. Rosenfeld RM, Kay D. Natural history of untreated otitis media. 
 Laryngoscope. 2003;113(10):1645–1657.
 7. Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM. 
Antibiotics for acute otitis media in children [review]. Cochrane 
Database Syst Rev. 2013;1:CD000219.
 8. Stool SE, Field MJ. The impact of otitis media. Pediatr Infect Dis J. 
1989;8(Suppl 1):S11–S14.
 9. Chesney J, Black A, Choo D. What is the best practice for acute 
 mastoiditis in children? Laryngoscope. Epub July 12, 2013.
 10. van Zon A, van der Heijden GJ, van Dongen TM, Burton MJ, 
Schilder AG. Antibiotics for otitis media with effusion in children 
[review]. Cochrane Database Syst Rev. 2012;9:CD009163.
 11. Kubba H, Pearson JP, Birchall JP. The aetiology of otitis media with 
effusion: a review. Clin Otolaryngol Allied Sci. 2000;25(3):181–194.
 12. Finkelstein Y, Ophir D, Talmi YP, Shabtai A, Strauss M, Zohar Y. 
Adult onset otitis media with effusion. Arch Otolaryngol Head Neck 
Surg. 1994;120(5):517–527.
 13. Reiss M, Reiss G. [Supparative chronic otitis media: etiology, diagnosis 
and therapy]. Med Monatsschr Pharm. 2010;33(1):11–16; quiz 17–18. 
German.
 14. Klein JO. Epidemiology of otitis media. Pediatr Infect Dis J. 
1989;8(Suppl 1):S9.
 15. American Academy of Family Physicians; American Academy of 
Otolaryngology-Head and Neck Surgery; American Academy of 
Pediatrics Subcommittee on Otitis Media With Effusion. Otitis media 
with effusion. Pediatrics. 2004;113(5):1412–1429.
 16. Renko M, Kristo A, Tapiainen T, et al. Nasopharyngeal dimensions 
in magnetic resonance imaging and the risk of acute otitis media. 
J Laryngol Otol. 2007;121(9):853–856.
 17. Coates HL, Morris PS, Leach AJ, Couzos S. Otitis media in Aboriginal 
children: tackling a major health problem. Med J Aust. 2002;177(4): 
177–178.
 18. Koch A, Homøe P, Pipper C, Hjuler T, Melbye M. Chronic suppurative 
otitis media in a birth cohort of children in Greenland: population-
based study of incidence and risk factors. Pediatr Infect Dis J. 
2011;30(1):25–29.
 19. Hoffman HJ, Daly KA, Bainbridge KE, et al. Panel 1: Epidemiology, 
natural history, and risk factors. Otolaryngol Head Neck Surg. 
2013;148(Suppl 4):E1–E25.
 20. MacIntyre EA, Heinrich J. Otitis media in infancy and development 
of asthma and atopic disease. Curr Allergy Asthma Rep. 2012;12(6): 
547–550.
Infection and Drug Resistance 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
23
Update on otitis media
 21. Macarthur CJ, Wilmot B, Wang L, Schuller M, Lighthall J, Trune D. 
Genetic susceptibility to chronic otitis media with effusion:  Candidate 
gene single nucleotide polymorphisms. Laryngoscope. Epub 
August 8, 2013.
 22. Rye MS, Wiertsema SP, Scaman ES, et al. FBXO11, a regulator of 
the TGFβ pathway, is associated with severe otitis media in Western 
Australian children. Genes Immun. 2011;12(5):352–359.
 23. World Health Organization. Chronic Suppurative Otitis Media. Burden of 
Illness and Management Options. Geneva: World Health Organization, 
2004. Available from: http://www.who.int/pbd/deafness/activities/ 
hearing_care/otitis_media.pdf. Accessed November 25, 2013.
 24. Fletcher MA, Fritzell B. Pneumococcal conjugate vaccines and 
otitis media: an appraisal of the clinical trials. Int J Otolaryngol. 
2012;2012:312935.
 25. Cayé-Thomasen P, Hermansson A, Bakaletz L, et al. Panel 3: Recent 
advances in anatomy, pathology, and cell biology in relation to otitis 
media pathogenesis. Otolaryngol Head Neck Surg. 2013;148(Suppl 4): 
E37–E51.
 26. Rovers MM, Schilder AG, Zielhuis GA, Rosenfeld RM. Otitis media. 
Lancet. 2004;363(9407):465–473.
 27. Murphy TF, Chonmaitree T, Barenkamp S, et al. Panel 5: 
 Microbiology and immunology panel. Otolaryngol Head Neck Surg. 
2013;148(Suppl 4):E64–E89.
 28. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir 
treatment of influenza in children 1–3 years of age: a randomized 
controlled trial. Clin Infect Dis. 2010;51(8):887–894.
 29. Pumarola F, Marès J, Losada I, et al. Microbiology of bacteria causing 
recurrent acute otitis media (AOM) and AOM treatment failure in young 
children in Spain: shifting pathogens in the post-pneumococcal conjugate 
vaccination era. Int J Pediatr Otorhinolaryngol. 2013;77(8):1231–1236.
 30. Chen YJ, Hsieh YC, Huang YC, Chiu CH. Clinical manifestations 
and microbiology of acute otitis media with spontaneous otorrhoea in 
children. J Microbiol Immunol Infect. 2013;46(5):382–388.
 31. Stol K, Verhaegh SJ, Graamans K, et al. Microbial profiling does 
not differentiate between childhood recurrent acute otitis media and 
chronic otitis media with effusion. Int J Pediatr Otorhinolaryngol. 
2013;77(4):488–493.
 32. Salomonsen RL, Hermansson A, Cayé-Thomasen P. Ossicular bone 
modeling in acute otitis media. Otol Neurotol. 2010;31(7):1109–1114.
 33. MacArthur CJ, Pillers DA, Pang J, Kempton JB, Trune DR. Altered 
expression of middle ear inner ear cytokines in mouse otitis media. 
Laryngoscope. 2011;121(2):365–371.
 34. Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial 
biofilms on the middle-ear mucosa of children with chronic otitis media. 
JAMA. 2006;12;296(2):202–211.
 35. Daniel M, Imtiaz-Umer S, Fergie N, Birchall JP, Bayston R. 
Bacterial involvement in otitis media with effusion. Int J Pediatr 
Otorhinolaryngol. 2012;76(10):1416–1422.
 36. Saafan ME, Ibrahim WS, Tomoum MO. Role of adenoid  biofilm 
in chronic otitis media with effusion in children. Eur Arch 
Otorhinolaryngol. 2013;270(9):2417–2425.
 37. Preciado D, Kuo E, Ashktorab S, Manes P, Rose M. Cigarette smoke 
activates NFκB-mediated Tnf-α release from mouse middle ear cells. 
Laryngoscope. 2010;120(12):2508–2515.
 38. Tasker A, Dettmar PW, Panetti M, Koufman JA, Birchall JP, 
Pearson JP. Reflux of gastric juice and glue ear in children. Lancet. 
2002;359(9305):493.
 39. Li JD, Hermansson A, Ryan AF, et al. Panel 4: Recent advances in otitis 
media in molecular biology, biochemistry, genetics, and animal models. 
Otolaryngol Head Neck Surg. 2013;148(Suppl 4):E52–E63.
 40. Marchisio P, Chonmaitree T, Leibovitz E, et al. Panel 7: Treatment 
and comparative effectiveness research. Otolaryngol Head Neck Surg. 
2013;148(Suppl 4):E102–E121.
 41. Scottish Intercollegiate Guidelines Network. Guidelines No 66. 
 Diagnosis and Management of Childhood Otitis Media in Primary 
Care. Edinburgh: Royal College of Physicians; 2003. Available from: 
http://www.sign.ac.uk/pdf/qrg66.pdf. Accessed October 30, 2013.
 42. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and 
 management of acute otitis media. Pediatrics. 2013;131(3):e964–e999.
 43. Whittemore KR Jr. What is the role of tympanostomy tubes in the 
treatment of recurrent acute otitis media? Laryngoscope. 2013; 
123(1):9–10.
 44. Bluestone CD, Cantekin EI. Design factors in the characterization and 
identification of otitis media and certain related conditions. Ann Otol 
Rhinol Laryngol Suppl. 1979;88(5 Pt 2 Suppl 60):13–28.
 45. To K, Harrison L, Daniel M. Management of otitis media with effusion 
and recurrent acute otitis media. The Otorhinolaryngologist. In press 
2013.
 46. Marcy M, Takata G, Shekelle P, et al. Management of Acute Otitis 
Media. Evidence Report/Technology Assessment No 15. Rockville, 
MD: Agency for Healthcare Research and Quality; 2001.
 47. Glasziou PP, Del Mar CB, Sanders SL, Hayem M. Antibiotics for 
acute otitis media in children [review]. Cochrane Database Syst Rev. 
2004;(1):CD000219.
 48. Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicro-
bial drugs for acute otitis media: metaanalysis of 5400 children from 
thirty-three randomized trials. J Pediatr. 1994;124(3):355–367.
 49. Damoiseaux RA, van Balen FA, Hoes AW, Verheij TJ, de Melker RA. 
Primary care based randomised double blind trial of amoxicillin versus 
placebo for acute otitis media in children aged under 2 years. BMJ. 
2000;320(7231):350–354.
 50. American Academy of Pediatrics Subcommittee on Management of 
Acute Otitis Media. Diagnosis and management of acute otitis media. 
Pediatrics. 2004;113(5):1451–1465.
 51. Rosenfeld RM, Schwartz SR, Pynnonen MA, et al. Clinical practice 
guideline: Tympanostomy tubes in children. Otolaryngol Head Neck 
Surg. Jul 2013;149(Suppl 1):S1–S35.
 52. Leach AJ, Morris PJ. Antibiotics for the prevention of acute and chronic 
suppurative otitis media in children [review]. Cochrane Database Syst 
Rev. 2006;(4):CD004401.
 53. Surgical management of children with otitis media with effusion (OME) 
[webpage on the Internet]. London: National Institute for Health and 
Clinical Excellence; 2008 [updated May 30, 2012]. Available from: 
http://guidance.nice.org.uk/CG60. Accessed October 30, 2013.
 54. Daniel M, Kamani T, El-Shunnar S, et al. National Institute for Clinical 
Excellence guidelines on the surgical management of otitis media with 
effusion: are they being followed and have they changed practice? Int 
J Pediatr Otorhinolaryngol. 2013;77(1):54–58.
 55. Vlastarakos PV, Nikolopoulos TP, Korres S, Tavoulari E,  Tzagaroulakis A, 
Ferekidis E. Grommets in otitis media with effusion: the most frequent 
operation in children. But is it associated with significant complications? 
Eur J Pediatr. 2007;166(5):385–391.
 56. Daniel M, Chessman R, Al-Zahid S, et al. Biofilm eradication with 
biodegradable modified-release antibiotic pellets: a potential treat-
ment for glue ear. Arch Otolaryngol Head Neck Surg. 2012;138(10): 
942–949.
 57. van den Aardweg MT, Schilder AG, Herkert E, Boonacker CW, 
Rovers MM. Adenoidectomy for otitis media in children [review]. 
Cochrane Database Syst Rev. 2010;(1):CD007810.
 58. Woodfield G, Dugdale A. Evidence behind the WHO guidelines: 
hospital care for children: what is the most effective antibiotic regime 
for chronic suppurative otitis media in children? J Trop Pediatr. 
2008;54(3):151–156.
 59. Macfadyen CA, Acuin JM, Gamble C. Systemic antibiotics versus 
topical treatments for chronically discharging ears with underlying 
eardrum perforations [review]. Cochrane Database Syst Rev. 2006;(1): 
CD005608.
 60. Phillips JS, Yung MW, Burton MJ, Swain IR. Evidence review and 
ENT-UK consensus report for the use of aminoglycoside-containing 
ear drops in the presence of an open middle ear. Clin Otolaryngol. 
2007;32(5):330–336.
 61. Rye MS, Bhutta MF, Cheeseman MT, et al. Unraveling the genetics of 
otitis media: from mouse to human and back again. Mamm Genome. 
2011;22(1–2):66–82.
Infection and Drug Resistance
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/infection-and-drug-resistance-journal
Infection and Drug Resistance is an international, peer-reviewed open-
access journal that focuses on the optimal treatment of infection (bacte-
rial, fungal and viral) and the development and institution of preventive 
strategies to minimize the development and spread of resistance. The 
journal is specifically concerned with the epidemiology of antibiotic 
resistance and the mechanisms of resistance development and diffusion 
in both hospitals and the community. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Infection and Drug Resistance 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
24
Qureishi et al
 62. Cheeseman MT, Tyrer HE, Williams D, et al. HIF-VEGF pathways 
are critical for chronic otitis media in Junbo and Jeff mouse mutants. 
PLoS Genet. 2011;7(10):e1002336.
 63. Pelton SI, Pettigrew MM, Barenkamp SJ, et al. Panel 6: Vaccines. 
Otolaryngol Head Neck Surg. 2013;148(Suppl 4):E90–E101.
 64. Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M. Reduced 
physician claims for otitis media after implementation of pneumococcal 
conjugate vaccine program in the province of Quebec, Canada. Pediatr 
Infect Dis J. 2009;28(9):e271–e275.
 65. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-
related health care utilization by privately insured young children in 
the United States, 1997–2004. Pediatrics. 2008;121(2):253–260.
 66. Siber GR, Klugman KP, Mäkelä PH. Nasopharyngeal carriage. In: Siber 
GR, Klugman KP, Mäkelä PH, editors. Pneumococcal Vaccines: The Impact 
of Conjugate Vaccine. Washington, DC: ASM Press; 2008:279–300.
 67. Dunne EM, Smith-Vaughan HC, Robins-Browne RM, Mulholland EK, 
Satzke C. Nasopharyngeal microbial interactions in the era of pneumo-
coccal conjugate vaccination. Vaccine. 2013;31(19):2333–2342.
 68. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A 
pneumococcal strain not included in the 7-valent conjugate vaccine as 
an otopathogen in children. JAMA. 2007;298(15):1772–1778.
 69. Daniel M, Gautam S, Scrivener TA, Meller C, Levin B, Curotta J. 
What effect has pneumococcal vaccination had on acute mastoiditis? 
J Laryngol Otol. 2013;127 Suppl 1:S30–S34.
 70. Zangeneh TT, Baracco G, Al-Tawfiq JA. Impact of conjugate pneumoc-
cal vaccines on the changing epidemiology of pneumococcal infections. 
Expert Rev Vaccines. 2011;10(3):345–353.
 71. Levine OS, Cherian T, Hajjeh R, Knoll MD. Progress and future 
 challenges in coordinated surveillance and detection of pneumo-
coccal and Hib disease in developing countries. Clin Infect Dis. 
2009;48 Suppl 2:S33–S36.
 72. Cornick JE, Bentley SD. Streptococcus pneumoniae: The evolution of 
antimicrobial resistance to beta-lactams, fluoroquinolones, and mac-
rolides. Microbes Infect. 2012;14(7–8):573–583.
 73. Kaplan SL, Mason EO Jr. Management of infections due to 
antibiotic- resistant Streptococcus pneumoniae. Clin Microbiol Rev. 
1998;11(4):628–644.
 74. European Centre for Disease Prevention and Control.  Antimicrobial 
resistance surveillance in Europe 2009. Annual Report of the European 
Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: 
European Centre for Disease Prevention and Control; 2010. Available 
from: http://www.ecdc.europa.eu/en/publications/Publications/1011_
SUR_annual_EARS_Net_2009.pdf. Accessed November 25, 2013.
 75. European Centre for Disease Prevention and Control.  Antimicrobial 
resistance surveillance in Europe 2011. Annual Report of the European 
Antimicrobial Resistance Surveillance Network (EARS-Net).  Stockholm: 
European Centre for Disease Prevention and Control; 2012. Available 
from: http://www.ecdc.europa.eu/en/publications/ publications/antimi-
crobial-resistance-surveillance-europe-2011.pdf. Accessed November 
25, 2013.
 76. Sommerfleck P, González Macchi ME, Pellegrini S, et al. Acute otitis 
media in infants younger than three months not vaccinated against 
Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol. 2013;77(6): 
976–980.
 77. Pichichero ME. Otitis media. Pediatr Clin North Am. 2013;60(2): 
391–407.
 78. Lewis K. Persister cells: molecular mechanisms related to antibiotic 
tolerance. Handb Exp Pharmacol. 2012;(211):121–133.
 79. Seth AK, Geringer MR, Hong SJ, Leung KP, Mustoe TA, Galiano RD. 
In vivo modeling of biofilm-infected wounds: a review. J Surg Res. 
2012;178(1):330–338.
 80. Gates GA, Avery CA, Prihoda TJ, Cooper JC Jr. Effectiveness 
of adenoidectomy and tympanostomy tubes in the treatment of 
chronic otitis media with effusion. N Engl J Med. 1987;317(23): 
1444–1451.
 81. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. 
Lancet. 2001;358(9276):135–138.
 82. Ryder VJ, Chopra I, O’Neill AJ. Increased mutability of staphylococci 
in biofilms as a consequence of oxidative stress. PLoS One. 2012;7(10): 
e47695.
 83. Donlon RM, Costerton JW. Biofilms: survival mechanisms of clinically 
relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167–193.
 84. Hoskison E, Daniel M, Al-Zahid S, Shakesheff KM, Bayston R, 
 Birchall JP. Drug delivery to the ear. Ther Deliv. 2013;4(1):115–124.
 85. Khoo X, Simons EJ, Chiang HH, et al. Formulations for trans-tympanic 
antibiotic delivery. Biomaterials. 2013;34(4):1281–1288.
 86. Sarwar A, Nemirovski A, Shapiro B. Optimal Halbach permanent 
magnet designs for maximally pulling and pushing nanoparticles. 
J Magn Magn Mater. 2012;324(5):742–754.
 87. Jang CH, Park H, Cho YB, Choi CH. The effect of anti-adhesive packing 
agents in the middle ear of guinea pig. Int J Pediatr Otorhinolaryngol. 
2008;72(11):1603–1608.
